Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Purpura

ClinicalTrials.gov lists 600 trials for Purpura or a narrower condition beneath it.

MeSH D011693 Hemic and Lymphatic Diseases C15 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 52 Phase 1/2 Phase 1/2 27 Phase 2 Phase 2 152 Phase 2/3 Phase 2/3 14 Phase 3 Phase 3 124 Phase 4 Phase 4 32 Not applicable Not applicable 43 Observational Observational 152 Phase 1 Phase 1 52 Phase 1/2 Phase 1/2 27 Phase 2 Phase 2 152 Phase 2/3 Phase 2/3 14 Phase 3 Phase 3 124 Phase 4 Phase 4 32 Not applicable Not applicable 43 Observational Observational 152

Trials per phase

1 more section with rows

36 of the 600 trials are tagged with Purpura itself; the rest are tagged with a narrower condition beneath it.

Get the Purpura report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Purpura trials start? (28)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 58

1999: 1 trials (Phase 2 1) 2000: 5 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 2 2) 2001: 2 trials (Phase 3 1, Phase 2 1) 2002: 6 trials (Not applicable 1, Phase 3 2, Phase 2 2, Phase 1/2 1) 2003: 6 trials (Not applicable 1, Phase 2/3 1, Phase 2 3, Phase 1/2 1) 2004: 6 trials (Not applicable 1, Phase 3 3, Phase 2 2) 2005: 12 trials (Observational 2, Not applicable 1, Phase 3 6, Phase 2 1, Phase 1/2 1, Phase 1 1) 2006: 16 trials (Observational 4, Phase 3 5, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2007: 21 trials (Observational 4, Phase 3 6, Phase 2 6, Phase 1/2 2, Phase 1 3) 2008: 14 trials (Not applicable 1, Phase 3 4, Phase 2/3 2, Phase 2 6, Phase 1 1) 2009: 10 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 3, Phase 2 3) 2010: 20 trials (Observational 8, Not applicable 1, Phase 4 3, Phase 3 1, Phase 2 5, Phase 1 2) 2011: 19 trials (Observational 11, Phase 4 1, Phase 3 4, Phase 2 1, Phase 1 2) 2012: 25 trials (Observational 8, Not applicable 2, Phase 4 1, Phase 3 9, Phase 2 4, Phase 1 1) 2013: 17 trials (Observational 5, Not applicable 1, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1 2) 2014: 17 trials (Observational 3, Not applicable 1, Phase 3 8, Phase 2 2, Phase 1/2 1, Phase 1 2) 2015: 21 trials (Observational 6, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1/2 3) 2016: 20 trials (Observational 8, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 3) 2017: 24 trials (Observational 9, Not applicable 1, Phase 4 2, Phase 3 5, Phase 2 5, Phase 1 2) 2018: 25 trials (Observational 10, Not applicable 2, Phase 3 4, Phase 2 5, Phase 1/2 2, Phase 1 2) 2019: 27 trials (Observational 8, Not applicable 3, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 2 5, Phase 1 1) 2020: 28 trials (Observational 7, Not applicable 1, Phase 4 4, Phase 3 6, Phase 2 9, Phase 1 1) 2021: 39 trials (Observational 10, Not applicable 2, Phase 4 2, Phase 3 8, Phase 2/3 2, Phase 2 12, Phase 1/2 1, Phase 1 2) 2022: 41 trials (Observational 10, Not applicable 3, Phase 4 3, Phase 3 10, Phase 2/3 1, Phase 2 13, Phase 1 1) 2023: 38 trials (Observational 8, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2 18, Phase 1/2 1, Phase 1 3) 2024: 32 trials (Observational 10, Not applicable 3, Phase 3 1, Phase 2 9, Phase 1/2 1, Phase 1 8) 2025: 58 trials (Observational 11, Not applicable 4, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 11, Phase 1/2 9, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 42
2025 58
2024 32
2023 38
2022 41
2021 39
2020 28
2019 27
2018 25
2017 24

Showing 10 of 28 earlier years.

Start your 14-day trial Email me all 28 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 55 trials starting in 2026 and about 54 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 86 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 281 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Purpura trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 52
Phase 1/2 27
Phase 2 152
Phase 2/3 14
Phase 3 124
Phase 4 32
Not applicable 43
Observational 152
Expanded access 4

How many Purpura trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 43
Recruiting 110
Enrolling by invitation 2
Active, not recruiting 15
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Purpura trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 19
Novartis Pharmaceuticals 19
Amgen 18
Takeda 10
Eisai Inc. 8

Which drugs are being tested for Purpura? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Eltrombopag 51
RITUXIMAB 33
Romiplostim 29
Avatrombopag 16
Prednisone 12

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 40
rhTPO 9
Daratumumab SC 7
All-Trans Retinoid Acid(ATRA) 6
BLOOD SAMPLE 6

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Purpura trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Thrombocytopenia 156 40
Thrombotic thrombocytopenic purpura 75 5
Epistaxis 73 25
Pneumonia 61 23
Headache 47 25

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Purpura? (21)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Efficacy, tolerance and acceptability of pulsed dye laser on facial and neckline telangiectasias in systemic scleroderma: a prospective open-label monocentric study in 21 patients. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology 2023 Yes
Platelets, petechiae, and preservation of the vascular wall. The New England journal of medicine 2008 Yes
Minor complications after mandibular third molar surgery: type, incidence, and possible prevention. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2006 Yes
Diagnostic assessment of haemorrhagic rash and fever. Archives of disease in childhood 2001 Yes
The management of fever and petechiae: making sense of rash decisions. Archives of disease in childhood 2000 Yes

Showing 5 of 21 publications.

Start your 14-day trial Email me all 21 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages